title: Effect of follicularity on autologous transplantation for large-cell non-Hodgkin's lymphoma.
abstract: OBJECTIVE
  This study evaluated the outcomes of patients who received high-dose chemotherapy (HDC) and autologous hematopoietic stem-cell transplantation (ASCT) for large-cell non-Hodgkin's lymphoma (NHL) and the effect of a follicular versus a diffuse histology.
  
  
  METHODS
  The prognostic factors in 289 patients who underwent HDC and ASCT for large-cell NHL between May 1983 and December 1996 were analyzed.
  
  
  RESULTS
  With a median follow-up duration of 24 months for surviving patients (range, 3 to 131 months), 112 of 289 (39%) were alive and 82 of 289 (28%) were failure-free. In a multivariate analysis, the factors associated with a poorer failure-free survival (FFS) included a lactic dehydrogenase (LDH) level greater than normal (P < .0001), three or more prior chemotherapy regimens received (P < .01), a mass > or = 10 cm at transplant (P < .01), and diffuse histology at the time of transplant (P = .026). Patients who received HDC and ASCT for large-cell NHL in the good-prognosis category (normal LDH, < three prior chemotherapy regimens, no large mass, and not chemotherapy-resistant) had a 5-year survival rate of 45%. Within the good-prognosis group, patients with diffuse large-cell NHL had a 5-year survival rate of 42% compared with 58% for patients with follicular large-cell (FLC) lymphoma (P = .05).
  
  
  CONCLUSIONS
  Good-prognosis patients with FLC histology who receive HDC and ASCT have an improved survival compared with good-prognosis patients with a diffuse large-cell histology.
authors.affiliation: Department of Internal Medicine, University of Nebraska Medical Center, Omaha 69198-3332, USA. jmvose@mail.unmc.edu
authors.forename: J M
authors.initials: JM
authors.lastname: Vose
authors.forename: P J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: J C
authors.initials: JC
authors.lastname: Lynch
authors.forename: D D
authors.initials: DD
authors.lastname: Weisenburger
authors.forename: A
authors.initials: A
authors.lastname: Kessinger
authors.forename: W C
authors.initials: WC
authors.lastname: Chan
authors.forename: T C
authors.initials: TC
authors.lastname: Greiner
authors.forename: J O
authors.initials: JO
authors.lastname: Armitage
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008224:Lymphoma, Follicular / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis; D014182:Transplantation, Autologous